Scalable chromatographic strategies for mRNA and saRNA purification from IVT

The potential of RNA-based therapies continues to be explored in the vaccine segment, which has seen strong development during the COVID-19 pandemic, and beyond. Besides messenger RNA (mRNA), emerging RNA modalities such as self-amplifying RNA (saRNA) and circular RNA are gaining interest for their ability to reduce dosage or expand into new therapeutic areas. However, the structure and properties of these new RNA platforms bring challenges in production and purification.
This webinar focuses on affinity purification of RNA, and expands into development of new chromatography tools for purification of mRNA and saRNA. Case studies will delve into purification of mRNA, highlighting some of the challenges faced along the way. The webinar will cover optimizing affinity chromatography binding capacity up to 6 mg/mL, using non-affinity chromatographic methods for mRNA and saRNA (10,000 nt), and touch on supporting topics in the mRNA production workflow, such process monitoring, and reduction of dsRNA.
LEARN MORE ABOUT OUR mRNA SOLUTIONS:
www.biaseparat...
GET in TOUCH:
Webpage: www.biaseparat...
E-mail: [e-mail]
Tech support: [e-mail]